Chronic Pain News

Millennium Laboratories , a San Diego-based provider of therapeutic drug monitoring and education to physicians and staff treating chronic pain patients, has signed an agreement with Three Rivers Provider Network , a Preferred Provider Organization network in the United States.

Main Category: Pain / Anesthetics Also Included In: GastroIntestinal / Gastroenterology Article Date: 30 Nov 2009 - 3:00 PST Adolor Corporation announced the initiation of clinical testing of ADL7445, its proprietary, oral mu opioid receptor antagonist for the treatment of Opioid Bowel Dysfunction .

Main Category: Pain / Anesthetics Also Included In: Seniors / Aging Article Date: 25 Nov 2009 - 1:00 PST Older adults who reported chronic musculoskeletal pain in two or more locations, higher levels of severe pain, or pain that interfered with daily activities were more likely to experience a fall than adults who did not reports these types of ...

Raptor Pharmaceutical Corp. today announced the presentation of clinical trial data on NGX426, the Company's orally administered, non-opioid, AMPA/kainate receptor antagonist, at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, held on November 20-21 in San Francisco.

The husband of a woman who died when a Duragesic patch failed, causing her death, has filed suit in Grundy County Circuit Court.

Updated May 18, 2006 Capsaicin A chemical that may help relieve chronic pain. Capsaicin is found in capsicum peppers, which include cayenne peppers, red peppers, African chilies, and tabasco peppers.

Main Category: Pain / Anesthetics Also Included In: Medical Devices / Diagnostics ; Back Pain Article Date: 19 Nov 2009 - 15:00 PST St.

People who suffer from depression are much more likely to be prescribed powerful opioid painkillers like morphine and codeine and to stay on the drugs long-term, new research shows.

Main Category: Pain / Anesthetics Also Included In: Clinical Trials / Drug Trials Article Date: 18 Nov 2009 - 0:00 PST Winston Laboratories, Inc.

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven by the continued dominance of opioids that include immediate-release morphine and novel fast acting opioid reformulations, the cancer pain drug market will increase from $2.3 billion in 2008 to $3.7 billion in 2018 ...

WOODCLIFF LAKE, N.J. The Food and Drug Administration has approved a generic version of a chronic pain drug.

Chronic pain patients with a history of depression are three times more likely to receive long-term prescriptions for opioid medications like Vicodin compared to pain patients who do not suffer from depression, according to new research.

Millennium Laboratories, a leading provider of therapeutic drug monitoring and education to physicians and staff treating chronic pain patients, announced today the company's development and validation of a clinical quantitative assay for the new drug tapentadol by liquid chromatography/tandem mass spectrometry .

The information in this column is intended forA informational purposes only, and does not constitute medical advice or recommendations by the author.A Please consult with your physician before making any lifestyle or medication changes, or if you have any other concerns regarding your health.

PanGenetics, an antibody development company which is developing PG110, a humanized antibody to Nerve Growth Factor , today announced it has entered into an agreement with Abbott under which Abbott will acquire the global rights to this novel biologic.

Many people have few effective options to treat chronic pain, but a new pain-management technique may offer hope and much-needed relief.

The popular saying a more pain, more gaina might hold some truth for people suffering from chronic pain, for a new study has revealed that aggressive physiotherapy program often leads to far better results than a more cautious pain-free approach.

Abbott announced today a definitive agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor , expanding the company's pain care portfolio and leveraging its expertise in biologics.

Many Americans deal with some form of pain on a daily basis, whether it be from chronic lower back pain, headaches, or pain related to conditions such as cancer.

Chronic pain costs the United States more than $100 billion a year in direct medical costs and lost productivity, and it leads to more than 50 million lost workdays annually.